RESUMEN
An advanced small bowel mucinous adenocarcinoma with Peutz-Jeghers syndrome was resected, and we started capecitabine plus oxaliplatin (CapeOX) as adjuvant therapy. However, local recurrence was noted, and the tumor increased even after CapeOX plus bevacizumab and fluorouracil plus leucovorin plus irinotecan plus panitumumab (FOLFIRI plus panitumumab). Pembrolizumab was administered after confirming high-frequency microsatellite instability, and the tumor shrank markedly and remained shrunk for 20 months.
Asunto(s)
Adenocarcinoma Mucinoso , Neoplasias Colorrectales , Síndrome de Peutz-Jeghers , Adenocarcinoma Mucinoso/tratamiento farmacológico , Anticuerpos Monoclonales Humanizados , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Bevacizumab/uso terapéutico , Camptotecina/uso terapéutico , Fluorouracilo/uso terapéutico , Humanos , Leucovorina/uso terapéutico , Recurrencia Local de Neoplasia , Síndrome de Peutz-Jeghers/tratamiento farmacológicoRESUMEN
LESSONS LEARNED: Motivating patients to enroll in chemopreventive studies is challenging.Chemoprevention with toxic drugs is not feasible. BACKGROUND: LKB1 mutations are the underlying genetic abnormality causing Peutz-Jeghers syndrome (PJS) and are a potential target for everolimus. In this phase II study, the efficacy of everolimus on polyp and tumor growth in PJS patients was investigated. METHODS: Adult patients with a proven LKB1 mutation and who were suitable for everolimus treatment were included in two different PJS cohorts: (a) patients with unresectable malignancies and (b) patients with high-risk polyps. Treatment in both groups was oral everolimus, 10 mg daily. Response rates were primary endpoints for both cohorts. RESULTS: Between October 2011 and April 2016, only two patients were enrolled, one in each cohort. A 49-year-old patient with advanced pancreatic cancer in cohort 1 was progressive after 2 months. A 52-year-old male patient in cohort 2 experienced severe toxicity and refused treatment after 4 months, even though endoscopy suggested stabilization of polyps. Adverse events included dental inflammations, mucositis, and rash. In 2016, the trial was aborted for lack of accrual, despite extensive accrual efforts in an area where PJS is highly prevalent and care is highly centralized. CONCLUSION: Due to accrual problems, no conclusions can be drawn about the value of everolimus in PJS treatment, questioning the feasibility of this agent for chemoprevention.
Asunto(s)
Antineoplásicos/uso terapéutico , Everolimus/uso terapéutico , Pólipos Intestinales/prevención & control , Síndrome de Peutz-Jeghers/tratamiento farmacológico , Síndrome de Peutz-Jeghers/prevención & control , Quinasas de la Proteína-Quinasa Activada por el AMP , Antineoplásicos/administración & dosificación , Antineoplásicos/efectos adversos , Quimioprevención , Everolimus/administración & dosificación , Everolimus/efectos adversos , Humanos , Pólipos Intestinales/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Mutación , Neoplasias Pancreáticas/tratamiento farmacológico , Neoplasias Pancreáticas/genética , Neoplasias Pancreáticas/patología , Síndrome de Peutz-Jeghers/genética , Síndrome de Peutz-Jeghers/patología , Proteínas Serina-Treonina Quinasas/genéticaRESUMEN
Peutz-Jeghers syndrome (PJS) is inherited as an autosomal dominant trait characterized by multiple gastrointestinal hamartomatous polyps, mucocutaneous pigmentation, and an increased risk of neoplasm. Large-cell calcifying Sertoli cell tumor (LCCSCT) is a kind of sex cord-stromal tumor which may co-exist with PJS and which is characterized radiologically by calcification foci within the testes. Surgical treatment options for this tumor range from testis-preserving surgery to radical orchiectomy. Not with standing this invasive approach, recently, there are some case reports demonstrating the efficacy of aromatase inhibitors in avoiding orchiectomy and its associated complications. In this paper, we have presented a LCCSCT case diagnosed in a boy with PJS and his response to anastrozole treatment.
Asunto(s)
Nitrilos/uso terapéutico , Síndrome de Peutz-Jeghers/tratamiento farmacológico , Tumor de Células de Sertoli/tratamiento farmacológico , Neoplasias Testiculares/tratamiento farmacológico , Triazoles/uso terapéutico , Anastrozol , Inhibidores de la Aromatasa/uso terapéutico , Niño , Ginecomastia/complicaciones , Ginecomastia/tratamiento farmacológico , Humanos , Masculino , Síndrome de Peutz-Jeghers/complicaciones , Tumor de Células de Sertoli/complicaciones , Neoplasias Testiculares/complicaciones , Resultado del TratamientoAsunto(s)
Enanismo Hipofisario/tratamiento farmacológico , Hormona del Crecimiento/efectos adversos , Hormona del Crecimiento/uso terapéutico , Síndrome de Peutz-Jeghers/tratamiento farmacológico , Síndrome de Peutz-Jeghers/genética , Síndrome de Peutz-Jeghers/patología , Quinasas de la Proteína-Quinasa Activada por el AMP , Adolescente , Relación Dosis-Respuesta a Droga , Enanismo Hipofisario/complicaciones , Enanismo Hipofisario/patología , Endoscopía Gastrointestinal/métodos , Hormona del Crecimiento/administración & dosificación , Humanos , Proteína 3 de Unión a Factor de Crecimiento Similar a la Insulina/metabolismo , Factor I del Crecimiento Similar a la Insulina/metabolismo , Masculino , Mutación Missense/genética , Síndrome de Peutz-Jeghers/complicaciones , Síndrome de Peutz-Jeghers/cirugía , Proteínas Serina-Treonina Quinasas/genéticaAsunto(s)
Poliposis Adenomatosa del Colon/diagnóstico , Poliposis Adenomatosa del Colon/cirugía , Neoplasias Colorrectales Hereditarias sin Poliposis/diagnóstico , Neoplasias Colorrectales Hereditarias sin Poliposis/cirugía , Poliposis Adenomatosa del Colon/tratamiento farmacológico , Poliposis Adenomatosa del Colon/genética , Antineoplásicos/uso terapéutico , Colectomía , Neoplasias Colorrectales Hereditarias sin Poliposis/tratamiento farmacológico , Neoplasias Colorrectales Hereditarias sin Poliposis/genética , Reparación de la Incompatibilidad de ADN , Humanos , Ileostomía , Síndrome de Peutz-Jeghers/diagnóstico , Síndrome de Peutz-Jeghers/tratamiento farmacológico , Síndrome de Peutz-Jeghers/genética , Síndrome de Peutz-Jeghers/cirugíaRESUMEN
PURPOSE OF REVIEW: The aim of this review is to describe the clinical, biochemical, radiographic, histological, and functional characteristics of large-cell calcifying Sertoli cell tumors of the testes (LCCSCTs). We describe the two main syndromes associated with these tumors: Peutz-Jeghers syndrome (PJS) caused mainly by mutations in the STK11 (aka LKB1) gene, which encodes a serine-threonine kinase, and Carney complex (CNC), which is most often caused by PRKAR1A mutations, the gene encoding regulatory subunit type 1 of protein kinase A. RECENT FINDINGS: Relatively few patients have been reported in the literature with LCCSCTs. In children they often present as prepubertal and/or peripubertal gynecomastia. Although these tumors are very rare, they occur with higher frequency among patients with PJS and CNC. Orchiectomy was often performed in the past; however, these tumors are overwhelmingly benign and, unless there are significant hormonal changes or pain and/or mass effects, there is no need for surgery. Tumors that lead to hyperestrogenemia may be treated efficiently with aromatase inhibitors; any change in appearance should prompt evaluation for malignancy. SUMMARY: The detection of LCCSCTs may point to an underlying genetic multiple neoplasia syndrome such as PJS or CNC. Surgery is rarely indicated and aromatase inhibitors constitute an effective treatment for those cases that are associated with gynecomastia and/or advanced skeletal age.
Asunto(s)
Complejo de Carney/diagnóstico , Síndrome de Peutz-Jeghers/diagnóstico , Tumor de Células de Sertoli/diagnóstico , Neoplasias Testiculares/diagnóstico , Testículo/patología , Adolescente , Inhibidores de la Aromatasa/uso terapéutico , Complejo de Carney/tratamiento farmacológico , Complejo de Carney/patología , Niño , Preescolar , Ginecomastia/etiología , Humanos , Masculino , Síndrome de Peutz-Jeghers/complicaciones , Síndrome de Peutz-Jeghers/tratamiento farmacológico , Síndrome de Peutz-Jeghers/patología , Tumor de Células de Sertoli/complicaciones , Tumor de Células de Sertoli/tratamiento farmacológico , Tumor de Células de Sertoli/patología , Neoplasias Testiculares/complicaciones , Neoplasias Testiculares/tratamiento farmacológico , Neoplasias Testiculares/patología , Adulto JovenRESUMEN
Aromatase, an enzyme located in the endoplasmic reticulum of estrogen-producing cells, catalyzes the rate-limiting step in the conversion of androgens to estrogens in many tissues. The clinical features of patients with defects in CYP19A1, the gene encoding aromatase, have revealed a major role for this enzyme in epiphyseal plate closure, which has promoted interest in the use of inhibitors of aromatase to improve adult height. The availability of the selective aromatase inhibitors letrozole and anastrozole--currently approved as adjuvant therapy for breast cancer--have stimulated off-label use of aromatase inhibitors in pediatrics for the following conditions: hyperestrogenism, such as aromatase excess syndrome, Peutz-Jeghers syndrome, McCune-Albright syndrome and functional follicular ovarian cysts; hyperandrogenism, for example, testotoxicosis (also known as familial male-limited precocious puberty) and congenital adrenal hyperplasia; pubertal gynecomastia; and short stature and/or pubertal delay in boys. Current data suggest that aromatase inhibitors are probably effective in the treatment of patients with aromatase excess syndrome or testotoxicosis, partially effective in Peutz-Jeghers and McCune-Albright syndrome, but probably ineffective in gynecomastia. Insufficient data are available in patients with congenital adrenal hyperplasia or functional ovarian cysts. Although aromatase inhibitors appear effective in increasing adult height of boys with short stature and/or pubertal delay, safety concerns, including vertebral deformities, a decrease in serum HDL cholesterol levels and increase of erythrocytosis, are reasons for caution.
Asunto(s)
Inhibidores de la Aromatasa/farmacología , Inhibidores de la Aromatasa/uso terapéutico , Estatura/efectos de los fármacos , Desarrollo Infantil/efectos de los fármacos , Factores de Edad , Animales , Inhibidores de la Aromatasa/efectos adversos , Estatura/fisiología , Niño , Desarrollo Infantil/fisiología , Femenino , Humanos , Hiperandrogenismo/tratamiento farmacológico , Hiperandrogenismo/metabolismo , Masculino , Síndrome de Peutz-Jeghers/tratamiento farmacológico , Síndrome de Peutz-Jeghers/metabolismoRESUMEN
Peutz-Jeghers syndrome (PJS) is a rare autosomal dominant disorder characterized by multiple gastrointestinal hamartomatous polyps, mucocutaneous pigmentation and increased predisposition to neoplasms. Endocrine manifestations in PJS include gynecomastia and advanced bone age due to estrogen production by large-cell calcifying Sertoli cell tumors (LSCT). We present two 9-year-old male monozygotic twins, with PJS, bilateral progressive prepubertal gynecomastia and testicular bilateral multifocal calcifications, suggesting a diagnosis of LSCT. Their father had PJS but no history of gynecomastia or testicular calcifications. No mutations were found in the tumor suppressor gene LKB1/STK11, which is responsible for about 60% of PJS cases. The genotype of the aromatase cytochrome P450 19, a key enzyme involved in estrogen biosynthesis, was the same in the father and his twins. To reduce gynecomastia and delay skeletal maturation, the children started treatment with anastrozole, an aromatase inhibitor. Growth velocity decreased and gynecomastia diminished. After 2 years of treatment, anastrozole is still currently used at a dosage of 1 mg once daily with no side effects. In this study, a couple of monozygotic twins with PJS, prepubertal gynecomastia and LSCT is reported for the first time and anastrozole appears to be an efficacious medical treatment, as an alternative to orchidectomy, to control the effects of estrogen excess.
Asunto(s)
Ginecomastia/diagnóstico , Ginecomastia/tratamiento farmacológico , Nitrilos/uso terapéutico , Síndrome de Peutz-Jeghers/diagnóstico , Síndrome de Peutz-Jeghers/tratamiento farmacológico , Triazoles/uso terapéutico , Gemelos Monocigóticos , Anastrozol , Inhibidores de la Aromatasa/uso terapéutico , Niño , Enfermedades en Gemelos/diagnóstico , Enfermedades en Gemelos/tratamiento farmacológico , Enfermedades en Gemelos/genética , Genética , Ginecomastia/complicaciones , Ginecomastia/genética , Humanos , Masculino , Síndrome de Peutz-Jeghers/complicaciones , Síndrome de Peutz-Jeghers/genética , Pubertad/fisiología , Análisis de Secuencia de ADN , Factores de TiempoRESUMEN
Patients with Peutz-Jeghers syndrome (PJS) are affected by hamartomatous intestinal polyposis and increased risk of cancers in multiple organs caused by germline mutations in the tumour suppressor gene LKB1. Murine models that recapitulate aspects of PJS have been created. Here we examine the therapeutic effect of rapamycin, a macrolide with anti-tumourigenic and anti-angiogenic properties, in reducing tumour incidence in a large cohort of Lkb1(+/-) mice. To study the influence of early intervention, the animals were dosed with rapamycin from the age of 8 weeks, well before the onset of polyposis. These mice continued to receive the drug, which was well tolerated, throughout their lives. At sacrifice, we observed a reduction in gastric tumour burden in the rapamycin-treated mice (p = 0.0001) compared with age- and sex-matched controls. Treated animals also have a lower number of polyps per mouse than controls. In the polyps from the treated mice, phosphorylation of ribosomal p70 S6 kinase was maintained, while the phosphorylation of AKT at serine-473 was elevated, suggesting that mTORC1 function is maintained at this dosage. Despite this, a significant reduction in microvessel density was seen in polyps from the rapamycin-treated mice compared to those from the control mice (p = 5 x 10(-5)), suggesting that the anti-angiogenic effect of rapamycin played a role in polyp reduction. Overall, we demonstrated that prolonged oral administration of rapamycin from an early age is effective in lowering tumour burden in the Lkb1(+/-) mice without evident side effects.
Asunto(s)
Antibióticos Antineoplásicos/uso terapéutico , Síndrome de Peutz-Jeghers/tratamiento farmacológico , Sirolimus/uso terapéutico , Proteínas Quinasas Activadas por AMP , Administración Oral , Animales , Western Blotting/métodos , Mutación de Línea Germinal , Hibridación in Situ , Etiquetado Corte-Fin in Situ , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Microvasos , Neovascularización Patológica/tratamiento farmacológico , Síndrome de Peutz-Jeghers/patología , Proteínas Serina-Treonina Quinasas/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/métodos , Carga TumoralRESUMEN
PURPOSE: Peutz-Jeghers syndrome (PJS) is a unique disorder characterized by the development of hamartomas in the gastrointestinal tract as well as increased risks for variety of malignancies. Germ-line mutations of LKB1 cause PJS. We have generated Lkb1+/- mice, which model human PJS. Rapamycin and its analogues are promising preventive and therapeutic agents that specifically inhibit signaling from mammalian target of rapamycin (mTOR). Hyperactivation of mTOR signaling has been associated with PJS. The objective of the study is to investigate the efficacy of mTOR inhibition in suppressing Peutz-Jeghers polyposis in Lkb1+/- mice. EXPERIMENTAL DESIGN: We initiated a trial of rapamycin in Lkb1+/- mice at 9 months of age (after the onset of polyposis) at the dose of 2 mg/kg/d for a 2-month period. We assessed the efficacy of rapamycin by measuring polyp sizes and tumor burden. To examine the effect of rapamycin on mTOR signaling, phosphorylation levels of S6 were evaluated by immunostaining. RESULTS: We observed a significant decrease in mean tumor burden (Student's t test, P = 0.023) as well as total tumor burden in rapamycin-treated group compared with control group. Comparison of the polyp size observed in both rapamycin-treated and control groups showed that rapamycin efficiently decreased the tumor burden of large polyps (> 8 mm). This inhibition of rapamycin was associated with a decrease in phosphorylated S6 levels in the polyps. CONCLUSIONS: Rapamycin effectively suppresses Peutz-Jeghers polyposis in a mouse model, suggesting that rapamycin or its analogues may represent a new targeted therapy for the treatment of PJS.
Asunto(s)
Inmunosupresores/uso terapéutico , Síndrome de Peutz-Jeghers/tratamiento farmacológico , Proteínas Quinasas/efectos de los fármacos , Sirolimus/uso terapéutico , Proteínas Quinasas Activadas por AMP , Animales , Inmunohistoquímica , Ratones , Ratones Noqueados , Síndrome de Peutz-Jeghers/patología , Proteínas Quinasas/metabolismo , Proteínas Serina-Treonina Quinasas/genética , Transducción de Señal/efectos de los fármacos , Serina-Treonina Quinasas TORRESUMEN
BACKGROUND: Peutz-Jeghers syndrome (PJS) is a rare autosomal-dominant disorder characterized by multiple gastrointestinal hamartomatous polyps, mucocutaneous pigmentation and increased predisposition to various neoplasms. Endocrine manifestations in PJS include gynecomastia due to calcified Sertoli cell testicular tumors usually referred to as large-cell calcifying Sertoli cell tumors (LSCT). OBJECTIVE: To evaluate the value of endocrine markers and aromatase inhibitor treatment in children with PJS and LSCT. DESIGN AND SETTING: Familial cases, followed in a tertiary care center. PATIENTS: Two male siblings aged 7 and 9 years with PJS and LSCT. INTERVENTION: Third generation aromatase inhibitor (anastrozole) in one of the patients. MAIN OUTCOME MEASURES: Longitudinal measurements of sex-steroids, gonadotropins, Sertoli cell markers and auxological evaluation. RESULTS: The two male siblings with PJS had similar bilateral multifocal testicular calcifications and biochemical evidence of Sertoli cell dysfunction manifested by elevated plasma inhibin-alpha levels. Only one sibling had gynecomastia. Estradiol levels were normal in both. During treatment with anastrozole, estradiol levels, growth and skeletal maturation, as well as Sertoli cell markers (inhibin B, inhibin-alpha and anti-Mullerian hormone) decreased. CONCLUSIONS: Inhibin-alpha may be considered as a marker for LSCT in children with PJS, pointing to a specific defect in inhibin regulation in this condition. Moreover, the decrease in Sertoli cell markers during aromatase inhibitor treatment suggests that increased estrogen production is a primary event regulating downstream production of Sertoli cell peptides. Anastrozole is efficient in controlling the clinical features of the disease and should be proposed as an alternative to bilateral orchidectomy, which is often performed in this condition.
Asunto(s)
Inhibidores de la Aromatasa/uso terapéutico , Ginecomastia/tratamiento farmacológico , Ginecomastia/genética , Nitrilos/uso terapéutico , Síndrome de Peutz-Jeghers/tratamiento farmacológico , Síndrome de Peutz-Jeghers/genética , Triazoles/uso terapéutico , Anastrozol , Hormona Antimülleriana , Niño , ADN/química , ADN/genética , Femenino , Glicoproteínas/sangre , Ginecomastia/patología , Humanos , Inhibinas/sangre , Estudios Longitudinales , Masculino , Linaje , Penetrancia , Síndrome de Peutz-Jeghers/patología , Análisis de Secuencia de ADN , Tumor de Células de Sertoli/tratamiento farmacológico , Tumor de Células de Sertoli/genética , Tumor de Células de Sertoli/patología , Hormonas Testiculares/sangreRESUMEN
Peutz-Jeghers syndrome (PJS) is a rare disorder characterized by benign intestinal hamartomatous polyps and mucocutaneous pigmentation, and with an increased risk for intestinal and extra-intestinal neoplasms. Sertoli cell tumors in boys with PJS have been increasingly recognized as a cause of prepubertal gynecomastia. However, an association between nephrocalcinosis and PJS has not been reported before. We report on a 7.25-year-old boy with PJS, bilateral gynecomastia, Sertoli cell tumor and nephrocalcinosis, and present the outcome of 1-year treatment with the aromatase inhibitor testolactone. The patient presented with bilateral breast and testis enlargement, and mucocutaneous pigmentation. Testicular ultrasound revealed parenchymal multiple microcalcifications. Histopathological examination was consistent with Sertoli cell tumors. Nephrocalcinosis due to idiopathic renal hypercalciuria was also detected. The aromatase inhibitor testolactone was begun in an attempt to prevent acceleration in skeletal maturation. One-year treatment with testolactone reduced the breast base diameter from 7 to 3 cm, and bone age advanced 1.2 years during this period. Our case demonstrates that waiting for the effect of aromatase inhibitors on gynecomastia before making a decision for mastectomy may be a reasonable option. We also consider that the association between PJS and nephrocalcinosis may be a coincidence.
Asunto(s)
Inhibidores de la Aromatasa/uso terapéutico , Ginecomastia/complicaciones , Síndrome de Peutz-Jeghers/complicaciones , Tumor de Células de Sertoli/complicaciones , Neoplasias Testiculares/complicaciones , Testolactona/uso terapéutico , Niño , Ginecomastia/tratamiento farmacológico , Ginecomastia/etiología , Humanos , Masculino , Nefrocalcinosis/complicaciones , Síndrome de Peutz-Jeghers/tratamiento farmacológico , Tumor de Células de Sertoli/tratamiento farmacológico , Neoplasias Testiculares/tratamiento farmacológicoAsunto(s)
Inhibidores de la Ciclooxigenasa/administración & dosificación , Hamartoma/tratamiento farmacológico , Síndrome de Peutz-Jeghers/tratamiento farmacológico , Animales , Ensayos Clínicos como Asunto , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Hamartoma/genética , Hamartoma/prevención & control , Humanos , Ratones , Síndrome de Peutz-Jeghers/genética , Síndrome de Peutz-Jeghers/prevención & control , Proyectos Piloto , Pronóstico , Resultado del TratamientoRESUMEN
BACKGROUND & AIMS: Peutz-Jeghers syndrome (PJS) is typically manifested as severe gastrointestinal polyposis. Polyps in PJS patients and in Lkb1(+/-) mice that model PJS polyposis are frequently characterized by elevated cyclooxygenase-2 (COX-2). This study was designed to determine whether COX-2 inhibition would reduce tumor burden in Lkb1(+/-) mice or Peutz-Jeghers patients. METHODS: Genetic interactions between Cox-2 and Lkb1 in polyp formation were analyzed in mice with combined deficiencies in these genes. Pharmacologic inhibition of COX-2 was achieved by supplementing the diet of Lkb1(+/-) mice with 1500 ppm celecoxib between 3.5-10 and 6.5-10 months. In PJS patients, COX-2 was inhibited with a daily dose of 2 x 200 mg celecoxib for 6 months. RESULTS: Total polyp burden in Lkb1(+/-) mice was significantly reduced in a Cox-2(+/-) (53%) and in a Cox-2(-/-) (54%) background. Celecoxib treatment initiating before polyposis (3.5-10 months) led to a dramatic reduction in tumor burden (86%) and was associated with decreased vascularity of the polyps. Late treatment (6.5-10 months) also led to a significant reduction in large polyps. In a pilot clinical study, a subset of PJS patients (2/6) responded favorably to celecoxib with reduced gastric polyposis. CONCLUSIONS: These data establish a role for COX-2 in promoting Peutz-Jeghers polyposis and suggest that COX-2 chemoprevention may prove beneficial in the treatment of PJS.
Asunto(s)
Proteínas Portadoras , Inhibidores de la Ciclooxigenasa/uso terapéutico , Isoenzimas/antagonistas & inhibidores , Síndrome de Peutz-Jeghers/tratamiento farmacológico , Proteínas Serina-Treonina Quinasas , Proteínas/genética , Sulfonamidas/uso terapéutico , Proteínas Quinasas Activadas por AMP , Proteínas Adaptadoras Transductoras de Señales , Animales , Celecoxib , Ciclooxigenasa 2 , Inhibidores de la Ciclooxigenasa 2 , Modelos Animales de Enfermedad , Humanos , Péptidos y Proteínas de Señalización Intracelular , Isoenzimas/genética , Isoenzimas/fisiología , Proteínas de la Membrana , Ratones , Ratones Endogámicos C57BL , Microcirculación/efectos de los fármacos , Síndrome de Peutz-Jeghers/enzimología , Síndrome de Peutz-Jeghers/patología , Prostaglandina-Endoperóxido Sintasas/genética , Prostaglandina-Endoperóxido Sintasas/fisiología , PirazolesRESUMEN
OBJECTIVE: Laparotomy is the treatment of choice in Peutz-Jeghers Syndrome (PJS) patients for endoscopically irretrievable symptomatic polyps and polyp-related complications. During the last decade, we have operated on majority of the PJS patients with the purpose of removing all the gastrointestinal polyps (clean sweep), when an operation was indicated. The aim of this study is to evaluate the effect of clean sweep technique on the need for repeated surgery compared to a problem focused approach. PATIENTS AND METHODS: All patients with PJS treated in our institution since 1964 were studied. They were placed into two groups; those who had a problem-focused operation and those who were operated with the purpose of removing all small and large intestinal polyps. Demographics, presentation, follow-up period and the need for recurrent surgery were compared. RESULTS: We identified 11 patients (4 males, 7 females). Eight patients (5 females; median age 18.5) had problem-focused surgery for bleeding-anaemia (n = 3) or obstruction-intussusception (n = 5). These patients required 23 further operations within 87 patient-follow-up-years (2.64 operations per 10 years). Three patients (2 females; median age 6) were operated for bleeding-anaemia (n = 1) or obstruction-intussusception (n = 2) using the 'clean sweep' approach. These patients did not require any further surgery within 21 patient-follow-up-years. The gender, presentation and follow-up periods were similar between the groups. However, the 'clean sweep' technique appears to have reduced the need for further operations when it is compared with problem-focused approach (P = 0.01). CONCLUSION: To reduce the need for abdominal surgery and consequent problems in PJS patients, an attempt to remove all detected polyps (clean sweep technique) may be beneficial in these patients.
Asunto(s)
Endoscopía Gastrointestinal/métodos , Laparotomía/métodos , Síndrome de Peutz-Jeghers/tratamiento farmacológico , Síndrome de Peutz-Jeghers/cirugía , Adolescente , Adulto , Factores de Edad , Niño , Preescolar , Procedimientos Quirúrgicos del Sistema Digestivo/métodos , Femenino , Estudios de Seguimiento , Fármacos Gastrointestinales/uso terapéutico , Humanos , Masculino , Persona de Mediana Edad , Síndrome de Peutz-Jeghers/diagnóstico , Distribución de Poisson , Recurrencia , Sistema de Registros , Estudios Retrospectivos , Medición de Riesgo , Muestreo , Índice de Severidad de la Enfermedad , Factores Sexuales , Resultado del TratamientoRESUMEN
Inactivating germ-line mutations of LKB1 lead to Peutz-Jeghers syndrome (PJS). We have generated mice heterozygous for a targeted inactivating allele of Lkb1 and found that they develop severe gastrointestinal polyposis. In all cases, the polyps arising in the Lkb1+/- mice were found to be hamartomas that were histologically indistinguishable from polyps resected from PJS patients, indicating that Lkb1+/- mice model human PJS polyposis. No evidence for inactivation of the remaining wild-type Lkb1 allele in Lkb1+/- -associated polyps was observed. Moreover, polyps and other tissues in heterozygote animals exhibited reduced Lkb1 levels and activity, indicating that Lkb1 was haploinsufficient for tumor suppression. Analysis of the molecular mechanisms characterizing Lkb1+/- polyposis revealed that cyclooxygenase-2 (COX-2) was highly up-regulated in murine polyps concomitantly with activation of the extracellular signal-regulated kinases 1 and 2 (Erk1/2). Subsequent examination of a large series of human PJS polyps revealed that COX-2 was also highly up-regulated in the majority of these polyps. These findings thereby identify COX-2 as a potential target for chemoprevention in PJS patients.